Risperidone in the treatment of schizophrenia

American Journal of Psychiatry

Volumn 151, Issue 6, 1994, Pages 825-835

  Marder, Stephen R ^a   Meibach, Richard C ^b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO; RISPERIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SOMNOLENCE; TACHYCARDIA; VAGINITIS; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PIPERIDINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0028342655     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.151.6.825     Document Type: Article

References (29)

1. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
2. Seeman P: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1:133-152
3. Woolley DW, Shaw E: A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1954; 40:228-231
4. 2 receptor blocker. Drug Development Res 1986; 8:205-211
5. Niemegeers CJ, Awouters F, Janssen PA: Antagonisme de la sérotonine impliqué dans l'effet antipsychotique: confirmations par la ritansérine et le rispéridone. Encephale 1990; 16:147-151
6. 2 receptor blocking agent. Curr Ther Res 1986; 40:492-499
7. 2 antagonist, on Parkinsonian rest tremor. Curr Ther Res 1987; 41:298-300
8. 2 antagonist ritanserin in neuroleptic-induced Parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990; 13:500-506
9. Bleich A, Brown SL, Kahn R, van Praag HM: The role of serotonin in schizophrenia. Schizophr Bull 1988; 14:297-315
10. i values. J Pharmacol Exp Ther 1989; 251: 238-249
11. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ: Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247:661-670
12. Megens AAHP, Awouters FHL, Niemegeers CJE: Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol. Psychopharmacology (Bed) 1988; 95:493-496
13. 2 antagonist properties. J Pharmacol Exp Ther 1988; 244:685-693
14. Roose K, Gelders Y, Heylen S: Risperidone (R64 766) in psychotic patients: a first clinical therapeutic exploration. Acta Psychiatr Belg 1988; 88:233-241
15. 2 antagonist risperidone (R64 766) in the treatment of chronic psychosis: an open dose-finding study. Schizophr Res 1989; 2:411-415
16. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y: Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology (Berl) 1989; 99:445-449
17. Borison RL, Pathiraja AP, Diamond BI, Meibach RC: Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28:213-218
18. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
19. Kay SR, Opler LA: The positive-negative dimension in schizophrenia: its validity and significance. Psychiatr Dev 1987; 2:79-103
20. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
21. Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 1988; 23:99-110
22. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976
23. Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980; 7:233
24. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU): The UKU side effect rating scale: scale for the registration of unwanted effects of psychotropics. Acta Psychiatr Scand Suppl 1987; 334:81-94
25. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
26. SAS/STAT User's Guide, Version 6, 4th ed, vols 1, 2. Cary, NC, SAS Institute, 1990
27. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85:295-305
28. Müller-Spahn F and the International Risperidone Research Group: Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992; 15(suppl 1):90A-91A
29. Van Putten T, Marder SR, Mintz J: A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47:754-758